New Options Provide Physicians with Comprehensive Product Line from Single Source

New Catheter Completes Drainage Product Portfolio

QUEENSBURY, N.Y., Dec 15, 2009 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO) , a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will report its fiscal 2010 second quarter financial results on

VenaCure EVLT ™ , ClosureFAST ™ found to have similar efficacy, low pain and bruising

QUEENSBURY, N.Y., Nov 23, 2009 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today that it will present at the 21 st Annual Piper Jaffray Health Care

New Web Site on Varicose Veins is Launched by AngioDynamics at American College of Phlebology Congress VenaCure-EVLT.com offers practice development tools, helps patients find physicians QUEENSBURY, N.Y. November 5, 2009 - AngioDynamics (NASDAQ: ANGO) launched a new Web site at the American College

QUEENSBURY, N.Y., Oct 27, 2009 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced today it appointed Stephen J. McGill, 47, to a newly-created position, Senior

• Net Sales Increase 13% to $50.1 Million
• Net Income of $2.1 Million, or $0.09 EPS vs. $0.09 EPS in Q1FY09
• Conference Call Begins Today at 4:30 p.m. Eastern Time

AngioDynamics Introduces DuraMax™ Chronic Dialysis Catheter at 2009 CIRSE Scientific Meeting QUEENSBURY, N.Y. September 23, 2009 — AngioDynamics (NASDAQ: ANGO) has introduced the DuraMax™ stepped chronic dialysis catheter at the 2009 Cardiovascular and Interventional Radiological

AngioDynamics to Hold Fiscal 2010 First Quarter Financial Results Conference Call on October 6, 2009 QUEENSBURY, N.Y. --(BUSINESS WIRE)--Sep. 21, 2009-- AngioDynamics (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists and surgeons for the

AngioDynamics to Participate in the Canaccord Adams 29th Annual Growth Stock Conference QUEENSBURY, N.Y. --(BUSINESS WIRE)--Aug. 4, 2009-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease,

AngioDynamics Appoints Shawn McCarthy Senior Vice President and General Manager of Its Peripheral Vascular Business Unit QUEENSBURY, N.Y., Jul 21, 2009 (BUSINESS WIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of

Fourth Quarter Net Sales Increase 13% to $52.8 Million Fourth Quarter Net Income of $2.9 Million, or $0.12 EPS vs $0.02 EPS a Year Ago Fourth Quarter EPS of $0.14 Prior to Non-Recurring Costs, vs $0.19 a Year Ago Prior to Litigation Costs, Reflecting Investments in IRE Technology and Sales and Marketing Fourth Quarter Non GAAP EBITDA of $0.32 Per Share vs $0.12 Per Share a Year Ago Company Conference Call Begins Today at 4:30 p.m. Eastern Time

AngioDynamics to Hold Fiscal 2009 Fourth Quarter and Full Year Financial Results Conference Call on July 16, 2009 QUEENSBURY, N.Y. --(BUSINESS WIRE)--Jul. 2, 2009-- AngioDynamics, Inc. (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists and surgeons

Angiodynamics Offers New, High Flexibility Rfa Device For Cancer Tumor Ablation QUEENSBURY, N.Y. July 2, 2009 – The new StarBurst® XLi-Enhanced Semi-Flex probe from AngioDynamics (NASDAQ: ANGO) is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm

AngioDynamics to Participate in the Eighth Annual JMP Securities Research Conference QUEENSBURY, N.Y. --(BUSINESS WIRE)--May. 14, 2009-- AngioDynamics (NASDAQ:ANGO) , a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally-invasive

Jan Keltjens Appointed to Board of Directors of AngioDynamics QUEENSBURY, N.Y. --(BUSINESS WIRE)--May. 11, 2009-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally-invasive treatment of cancer and

AngioDynamics to Participate in the Bank of America and Merrill Lynch 2009 Health Care Conference QUEENSBURY, N.Y., May 07, 2009 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the

Results include fewer complications in patients treated with AngioDynamics device

AngioDynamics Reports Financial Results for Fiscal 2009 Third Quarter Net Sales Increase 21% to $49.4 Million Net Income of $1.9 Million and EPS of $0.08; EPS of $0.15 Prior to Expense Associated with Completion of CEO Transition (Non GAAP) EBITDA of $5.7 Million or $0.23 Per Share Conference Call